Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

| Press Release | No Comments
- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with selection…

Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event

| Press Release | No Comments
- Live moderated video webcast discussion among members of management and ADHD and abuse expert, Stephen V. Faraone, Ph.D., on Thursday, November 18th at 3:00 PM ET PHILADELPHIA, PA, Nov.…

Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference

| Press Release | No Comments
- Live video webcast presentation on Monday, November 15th at 8:30 am ET PHILADELPHIA, PA, Nov. 10, 2021 -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), ("Vallon" or the "Company"), a clinical-stage…

Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting

| Press Release | No Comments
- Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant medication - Company's lead…

Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements

| Press Release | No Comments
- Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR - Company's two…

Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board

| Press Release | No Comments
- Inaugural appointments include globally renowned leaders and experts on attention-deficit/hyperactivity disorder (ADHD) and stimulant abuse PHILADELPHIA, PA, Sept. 14, 2021 -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), ("Vallon" or the…

Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit

| Press Release | No Comments
Live video webcast with David Baker, President and CEO of Vallon, on Wednesday, August 18th 12:30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), ("Vallon"…

Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

| Press Release | No Comments
- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the ~$9…

Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR

| Press Release | No Comments
- Patent bolsters intellectual property protection as Company's partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 -- Vallon Pharmaceuticals…

Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

| Press Release | No Comments
- Company remains on track to report pivotal data from lead program, ADAIR, in second half 2021 - Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple drugs and…